[vc_row][vc_column css=”.vc_custom_1570720331401{margin-bottom: 20px !important;}”][vc_column_text]Aloka Srinivasan, Vice President, Regulatory Practice at Lachman Consultants recently wrote an article for PharmTech, detailing the Proactive Evaluation of Possible Genotoxic Impurities During the Early Stages of Drug Development. The article provides a direction for identifying genotoxic impurities early in the drug development process, regulating genotoxic impurities at acceptable levels in the API or drug product, and avoiding negative product regulation late in the development and/or marketing process, including expensive recalls.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”View The Full Article On PharmTech” color=”warning” align=”center” link=”url:http%3A%2F%2Fwww.pharmtech.com%2Fproactive-evaluation-possible-genotoxic-impurities-during-early-stages-drug-development|||”][/vc_column][/vc_row]
